Analysts/Institutional Investor Meet/Con. Call Updates

Date: November 02, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 544558 Dear Sir/Madam, Sub: Transcript of Earnings Conference Call held on Friday, October 30, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of the Earnings Conference Call held on Friday, October 30, 2026, at 02:00 p.m. (IST) to discuss the Company’s Unaudited Standalone and Consolidated Financial Results for the quarter and half- year ended September 30, 2026. Request you to take the above information on record. Thank you. Yours faithfully, For Fabtech Technologies Limited Hemant Mohan Anavkar Executive Director DIN: 00150776 Encl.: As mentioned above Fabtech Technologies Limited Q2 & H1 FY27 POST EARNINGS CONFERENCE CALL October 30, 2026 2:00 PM IST Management Team Mr. Ashwani Singh - Chief Executive Officer Mr. Aman Anavkar - Chief Growth Officer Mr. Chirag Doshi – Non - Executive Director Mr. Arihant Dhariwal - Head Investor Relations & Finance Strategy Call Coordinator Strategy & Investor Relations Consulting Fabtech Technologies Limited Q2 & H1 FY27 Post Earnings Conference Call October 30, 2026 2:00 PM IST Presentation Vinay Pandit: Ladies and gentlemen, on behalf of Kaptify Consulting Investor Relations Team, I welcome you all to the Q2 and H1 FY27 Post Earnings Conference Call of Fabtech Technologies Limited. Today on the call from the management team we have with us, Mr. Ashwani Singh, Chief Executive Officer; Mr. Aman Anavkar, Chief Growth Officer; Mr. Chirag Doshi, Non-Executive Director; and Mr. Arihant Dhariwal, Head Investor Relations and Finance. As a disclaimer, I would like to inform all of you that this call may contain forward-looking statements, which may involve risk and uncertainties, also a reminder that this call is being recorded. I would now request the management to brief us about the business and performance highlights for the period ended September 2026, the growth perspective and vision for the coming year, post which we will open the floor for Q&A. Over to the management team. Ashwani Singh: Thank you. Thanks. Thanks, Vinay. Good afternoon, everyone. And thank you for joining Fabtech Technologies Limited Q2 and H1 FY27 earnings call. The first half of FY27 has reinforced our confidence in the direction we have chosen and the business we are building. In Q2, consolidated revenue grew 22.8% sequentially to INR 92.09 crore and EBITDA more than doubled to INR 15.57 crore and the profitability strengthened significantly. Our order book remains robust at over INR 900 crore with a strong pipeline of opportunity across our core international market. We have navigated geopolitical disruption, protected our customer commitments and continued investing in the capabilities required for our next phase of growth. Our strategy is clear. We have established the infrastructure, strengthened our regional operations and positioned the organization to execute at a significantly larger scale. Our focus now is on accelerating execution, improving operating efficiencies and translating our order visibility into sustainable and profitable growth. We know where we are going and we have built the capabilities to get there and we are focused on delivery. With that, I invite Aman Anavkar, our Chief Growth Officer to take you through our business, global growth strategy and the opportunity shaping Fabtech's future. Over to you Aman. Page 2 of 27 Fabtech Technologies Limited Q2 & H1 FY27 Post Earnings Conference Call October 30, 2026 2:00 PM IST Aman Anavkar: Thank you. Good afternoon, everyone and thank you for joining us today. I am Aman Anavkar, Chief Growth Officer of Fabtech Technologies Limited. And I'll take you through our Q2 and H1 FY27 performance and how we see the rest of the year. And then we'll open up for your questions. For anyone that is new to Fabtech, here's the simplest way to understand us. Every vaccine, IV solution, tablet, capsule, biotech product is made inside a certified compliant facility. We are the ones responsible for designing, engineering, building and validating these facilities: start to finish, design and build for pharma companies, vaccine institutes, governments and private industries. We are a design and build organization focused in the pharmaceutical, healthcare and biotech industries, offering our in-house solutions where process, air and water is manufactured and designed under one roof. This gives us entire control over quality, speed and cost. We've worked in over 62 countries over the last three decades, have over 2,000 installations, more than 500 projects designed and built and we have a strong order book of INR 900 crores-plus. Our regional focus is in the pharmaceutical emerging markets. This is the Middle East, Africa, GCC and eco zones where pharmaceutical capability is needed. Now, jumping directly into the performance highlights, we've had an extremely strong EBITDA. I would say there are five things to take away from the quarter. Number one, the EBITDA more than doubled quarter on quarter to INR 155.7 million which is INR 15.57 crores in quarter two of FY27. We know and expect the revenue and margins to improve in H2 as the project milestones move into execution. Number three, we've started exploring and entering new markets with a new turnkey design and build project in the CIS region. Number four, we remain confident of an adjusted PAT margin of 8% to 9% at the end of FY27. And number five, we continue our participation in the largest stores globally such as CPHI Milan which is one of the most important platforms to engage with the industry stakeholders and have new conversations that will build our pipeline for the future. An operational update, H1 wasn't an easy environment. We dealt with geopolitical uncertainty and freight volatility across the GCC market. But that being said, we are proud that our UAE team kept every site running and every customer commitment on track. And we kept winning orders. This came at a cost. We put enhanced security and protective measures in place for our people on site which added to the Page 3 of 27 Fabtech Technologies Limited Q2 & H1 FY27 Post Earnings Conference Call October 30, 2026 2:00 PM IST installation costs this half. We'd make the same call again in the future. But the commitments remain on track and the performance goes steady. On the visibility, our order book stands at INR 900 crores and that's about 2.2 times last year's revenue. On top of the INR 900 crores, we're working on another INR 800 crores to INR 850 crores of added revenue over the next one year. We expect Africa and Saudi Arabia to be significant contributors to our pipeline. The initiatives are growing, advanced technology capabilities are increasing. We're focused on developing our cell and gene therapy capabilities, advanced high-tech facilities and data centre infrastructure. We're maintaining the execution, the cost control and the customer commitments and each region is being ring-fenced to further grow. That being said, I would like to hand over to Arihant for the detailed numbers. Over to you, Arihant. Arihant Dhariwal: Thanks, Aman. Move the slide to the next one. Let me take you through our financial performance for the second quarter of financial year '27 with a focus on sequential improvements over quarter 1. We have delivered a strong recovery in Q2 with improvement across revenue, EBITDA and profitability levels. Our revenue from operations have increased by 22.8% quarter on quarter from INR 749.8 million to INR 920.9 million in quarter 2. This reflects an improvement in project execution during the quarter. Total income grew by 24.8% from INR 781.5 million to [Showing first 8,000 characters — download PDF for full document]